Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celularity ( (CELU) ) has shared an announcement.
On April 17, 2026, Celularity amended its asset purchase and exclusive license agreement with NexGel, confirming total consideration of $13.3 million, including $8.3 million in cash at commencement and a $5.0 million convertible note, and revising milestone payment terms and certain contractual provisions. NexGel assumed sales representative obligations from the transaction start date, and Celularity extended the outside closing date to April 30, 2026, while adding new covenants on sales obligations, payments to insiders and disclosure limits.
In a related financing development, on April 16, 2026, investor Helena Global Investment Opportunities 1 Ltd. exchanged Celularity Series A preferred shares for a $1.97 million convertible promissory note, then on April 17, 2026 issued a default notice tied to Celularity’s late Form 10-K filing, exposing the company to potential default penalties if not cured within five business days. Celularity said it is evaluating the notice and intends to cure the alleged default, which otherwise could trigger a mandatory default amount and higher interest on the Helena note.
During April 2026, Celularity executed organizational changes linked to its strategic realignment and divestiture of its biomaterials business to NexGel, including the April 9, 2026 termination without cause of Senior Vice President and Chief Administrative Officer John R. Haines, effective May 8, 2026, and the April 15, 2026 resignation of President, Degenerative Diseases, Stephen A. Brigido. The leadership shake-up underscores a shift in resources toward the company’s core cell therapy platform and longevity-focused priorities as it exits non-core biomaterials operations.
On April 21, 2026, Celularity announced the closing of its previously disclosed transaction with NexGel, under which NexGel acquired commercial and other assets tied to Celularity’s biomaterials portfolio and secured an exclusive license to certain products. The deal provided Celularity $13.3 million in upfront cash and a note, the potential for up to $20 million in future milestones plus royalties, and facilitated the retirement of nearly $13 million of debt, strengthening its balance sheet while preserving economic upside in development-stage programs.
Chief executive Robert J. Hariri framed the NexGel transaction as a key step in sharpening Celularity’s strategic focus, monetizing non-core assets and reinforcing capital resources as it advances longevity-oriented cellular therapeutics. Taken together, the asset sale, financing developments and management changes indicate an aggressive pivot away from biomaterials and toward higher-value cell therapy programs, with near-term liquidity improvements counterbalanced by compliance-related financing risk highlighted by the Helena default notice.
The most recent analyst rating on (CELU) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The score is primarily weighed down by weak financial performance—large ongoing losses, declining revenue, and negative equity with meaningful debt. Technicals also point to a sustained downtrend with weak momentum. Valuation offers limited support given negative earnings and no dividend, while recent corporate events are mixed: liquidity improved via financing, but dilution/regulatory and shareholder constraints remain.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. is a Nasdaq-listed, longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. The company leverages the placenta’s biology, immunologic properties and scalable availability to target fundamental mechanisms of aging and age-related diseases.
Celularity’s business model centers on a therapeutic pipeline and manufacturing platform aimed at cellular therapeutics, while monetizing non-core biomaterials assets. Its market focus includes longevity medicine and age-related indications, positioning the company within the high-growth segment of advanced cell and gene therapies.
Average Trading Volume: 156,669
Technical Sentiment Signal: Sell
Current Market Cap: $36.05M
Learn more about CELU stock on TipRanks’ Stock Analysis page.